Patient characteristics
. | Lymphoid disease* . | Myeloid leukemia† . |
|---|---|---|
| Male:female | 68:40 | 64:48 |
| Mean age, y (range) | 33.1 (2-60) | 38.4 (4-59) |
| Disease | ||
| ALL, CR1 | 29 | NA |
| ALL, CR2 | 25 | NA |
| NHL, CR1 | 4 | NA |
| NHL, CR2 | 3 | NA |
| NHL, CR3+ | 6 | NA |
| NHL, progressive | 30 | NA |
| CLL, CR1 | 1 | NA |
| CLL, PR | 8 | NA |
| CLL, progressive | 2 | NA |
| AML, CR1 | NA | 28 |
| AML, CR2+ | NA | 8 |
| AML progressive | NA | 16 |
| CML, CP1 | NA | 43 |
| CML, CP2 | NA | 3 |
| CML, accelerated phase | NA | 3 |
| MDS, CR1 | NA | 2 |
| MDS, untreated | NA | 9 |
| TBI/cyclophosphamide or TBI/etoposide conditioning | 61 | 101 |
| Reduced intensity conditioning | 47 | 11 |
| Cyclosporin only as GVHD prophylaxis | 56 | 15 |
| Cyclosporin and methotrexate as GVHD prophylaxis | 52 | 97 |
. | Lymphoid disease* . | Myeloid leukemia† . |
|---|---|---|
| Male:female | 68:40 | 64:48 |
| Mean age, y (range) | 33.1 (2-60) | 38.4 (4-59) |
| Disease | ||
| ALL, CR1 | 29 | NA |
| ALL, CR2 | 25 | NA |
| NHL, CR1 | 4 | NA |
| NHL, CR2 | 3 | NA |
| NHL, CR3+ | 6 | NA |
| NHL, progressive | 30 | NA |
| CLL, CR1 | 1 | NA |
| CLL, PR | 8 | NA |
| CLL, progressive | 2 | NA |
| AML, CR1 | NA | 28 |
| AML, CR2+ | NA | 8 |
| AML progressive | NA | 16 |
| CML, CP1 | NA | 43 |
| CML, CP2 | NA | 3 |
| CML, accelerated phase | NA | 3 |
| MDS, CR1 | NA | 2 |
| MDS, untreated | NA | 9 |
| TBI/cyclophosphamide or TBI/etoposide conditioning | 61 | 101 |
| Reduced intensity conditioning | 47 | 11 |
| Cyclosporin only as GVHD prophylaxis | 56 | 15 |
| Cyclosporin and methotrexate as GVHD prophylaxis | 52 | 97 |